

# Mario Angelico

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8561982/publications.pdf>

Version: 2024-02-01

155  
papers

5,023  
citations

145106

33  
h-index

120465

65  
g-index

157  
all docs

157  
docs citations

157  
times ranked

6370  
citing authors

#	ARTICLE	IF	CITATIONS
1	Electronic Outpatient Referral System for Liver Transplant Improves Appropriateness and Allows First Visit Triage. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1388-e1415.	2.4	1
2	Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals. <i>JHEP Reports</i> , 2022, 4, 100462.	2.6	10
3	Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study. <i>Digestive and Liver Disease</i> , 2021, 53, 612-619.	0.4	6
4	Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. <i>Journal of Hepatology</i> , 2021, 74, 801-810.	1.8	26
5	On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites. <i>Journal of Hepatology</i> , 2021, 74, 340-349.	1.8	38
6	Tips for TIPS: A combined percutaneous and transjugular approach for intrahepatic portosystemic shunt placement after liver transplant. <i>Annals of Hepatology</i> , 2021, 22, 100162.	0.6	0
7	Resistance analysis and treatment outcomes in hepatitis C virus genotype 3â€infectected patients within the Italian network VIRONETâ€C. <i>Liver International</i> , 2021, 41, 1802-1814.	1.9	12
8	Sarcoâ€Model: A score to predict the dropout risk in the perspective of organ allocation in patients awaiting liver transplantation. <i>Liver International</i> , 2021, 41, 1629-1640.	1.9	17
9	2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virusâ€related infection before and after liver transplantation. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 583-605.	1.9	27
10	Cumulative incidence of solid and hematological De novo malignancy after liver transplantation in a multicentre cohort. <i>Annals of Hepatology</i> , 2021, 24, 100309.	0.6	4
11	Outcomes of Liver Transplant for Adults With Wilsonâ€™s Disease. <i>Liver Transplantation</i> , 2020, 26, 507-516.	1.3	12
12	Transarterial chemoembolization for hepatocellular carcinoma in Fontan surgery patient. <i>Radiology Case Reports</i> , 2020, 15, 2602-2606.	0.2	3
13	Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentasvir regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3349-3358.	1.3	13
14	Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 947-956.	5.1	166
15	A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition In Vitro. <i>Viruses</i> , 2020, 12, 251.	1.5	8
16	Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels <i>in vivo</i>, hinder HBsAg secretion <i>in vitro</i> and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection. <i>Emerging Microbes and Infections</i> , 2020, 9, 928-939.	3.0	5
17	Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program. <i>Scientific Reports</i> , 2019, 9, 585.	1.6	6
18	HCV resistance compartmentalization within tumoral and nonâ€tumoral liver in transplanted patients with hepatocellular carcinoma. <i>Liver International</i> , 2019, 39, 1986-1998.	1.9	6

#	ARTICLE	IF	CITATIONS
19	Daclatasvir, sofosbuvir with or without ribavirin for 24 weeks in hepatitis C genotype 3 cirrhosis: A real-life study. <i>Annals of Hepatology</i> , 2019, 18, 434-438.	0.6	8
20	A snapshot of virological presentation and outcome of immunosuppressionâ€driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infection. <i>Journal of Viral Hepatitis</i> , 2019, 26, 846-855.	1.0	9
21	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 394, 2184-2196.	6.3	818
22	Pitfalls in the reporting of upper endoscopy features in cirrhotic patients. <i>Digestive and Liver Disease</i> , 2019, 51, 382-385.	0.4	1
23	Acute Cholangitis with Atypical Clinical Presentation and Imaging. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1383-1385.	1.1	1
24	The evolving scenario of HBV infection and disease: A never-ending story. <i>Digestive and Liver Disease</i> , 2019, 51, 443-444.	0.4	0
25	Domino Liver Transplantation: Where are we Now?. <i>Reviews on Recent Clinical Trials</i> , 2019, 14, 183-188.	0.4	3
26	An Unusual Duodenal Polyp Causing Anemia in a Liver-Transplanted Patient. <i>American Journal of Gastroenterology</i> , 2018, 113, 918-919.	0.2	0
27	Impact of remnant vital tissue after locoregional treatment and liver transplant in hepatocellular cancer patients, a multicentre cohort study. <i>Transplant International</i> , 2018, 31, 988-998.	0.8	18
28	Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?. <i>Journal of Hepatology</i> , 2018, 68, 597-600.	1.8	28
29	Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for postâ€transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study. <i>Clinical Transplantation</i> , 2018, 32, e13165.	0.8	10
30	Trans-splenic Embolization Plus Partial Splenic Embolization for Management of Variceal Bleeding Due to Left-Sided Portal Hypertension. <i>Digestive Diseases and Sciences</i> , 2018, 63, 264-267.	1.1	7
31	Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. <i>Lancet, The</i> , 2018, 391, 2417-2429.	6.3	345
32	Repeated Transarterial Chemoembolization with Degradable Starch Microspheres (DSMs-TACE) of Unresectable Hepatocellular Carcinoma: A Prospective Pilot Study. <i>Current Medical Imaging</i> , 2018, 14, 637-645.	0.4	10
33	Lack of reduction in serum alphaâ€fetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hepatitis C virusâ€related cirrhosis. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1493-1500.	1.0	6
34	HDV Can Constrain HBV Genetic Evolution in HBsAg: Implications for the Identification of Innovative Pharmacological Targets. <i>Viruses</i> , 2018, 10, 363.	1.5	4
35	Multiclass <sc>HCV</sc> resistance to directâ€acting antiviral failure in realâ€life patients advocates for tailored secondâ€line therapies. <i>Liver International</i> , 2017, 37, 514-528.	1.9	84
36	Evidence of Spontaneous Post-transplant HCV Eradication in Two Failed DAA Treatments Awaiting Liver Transplantation. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2193-2195.	1.1	1

#	ARTICLE	IF	CITATIONS
37	HCV-RNA quantification in liver bioptic samples and extrahepatic compartments, using the abbott Real Time HCV assay. <i>Journal of Virological Methods</i> , 2017, 246, 1-7.	1.0	2
38	Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study. <i>Atherosclerosis</i> , 2017, 262, 179-184.	0.4	19
39	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 427-434.	3.7	15
40	Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens. <i>PLoS ONE</i> , 2017, 12, e0177352.	1.1	13
41	Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation <i>in vitro</i> . <i>Oncotarget</i> , 2017, 8, 15704-15715.	0.8	9
42	Kidney Transplantation in the Hepatitis C Infected Recipient. , 2017, , 653-663.		0
43	Complete hepatitis B virus prophylaxis withdrawal in hepatitis B surface antigen-“positive liver transplant recipients after longterm minimal immunosuppression. <i>Liver Transplantation</i> , 2016, 22, 1205-1213.	1.3	23
44	Crusted scabies in a liver transplant patient mimicking rupioid psoriasis. <i>European Journal of Dermatology</i> , 2016, 26, 495-496.	0.3	5
45	Portal vein thrombosis relevance on liver cirrhosis: Italian Venous Thrombotic Events Registry. <i>Internal and Emergency Medicine</i> , 2016, 11, 1059-1066.	1.0	90
46	International comparison of liver transplant programmes: differences in indications, donor and recipient selection and outcome between Italy and <sc>UK</sc>. <i>Liver International</i> , 2016, 36, 1481-1489.	1.9	8
47	Role of MRI with hepatospecific contrast agent in the identification and characterization of focal liver lesions: pathological correlation in explanted livers. <i>Radiologia Medica</i> , 2016, 121, 588-596.	4.7	13
48	TACE vs DEB-TACE: Who wins?. <i>Digestive and Liver Disease</i> , 2016, 48, 796-797.	0.4	10
49	Different expression of VEGF and EGFL7 in human hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2016, 48, 76-80.	0.4	14
50	Farewell from the Editors. <i>Digestive and Liver Disease</i> , 2015, 47, 995-996.	0.4	0
51	Standard bowel cleansing is highly ineffective in cirrhotic patients undergoing screening colonoscopy. <i>Digestive and Liver Disease</i> , 2015, 47, 523-525.	0.4	6
52	Recipient female gender is a risk factor for graft loss after liver transplantation for chronic hepatitis C: Evidence from the prospective Liver Match cohort. <i>Digestive and Liver Disease</i> , 2015, 47, 689-694.	0.4	17
53	Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice. <i>Digestive and Liver Disease</i> , 2015, 47, 233-241.	0.4	4
54	Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome. <i>Digestive and Liver Disease</i> , 2015, 47, 157-163.	0.4	5

#	ARTICLE	IF	CITATIONS
55	Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection. <i>Journal of Infection</i> , 2015, 70, 288-298.	1.7	11
56	Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression. <i>Hepatology</i> , 2015, 61, 823-833.	3.6	109
57	Downstaging disease in patients with hepatocellular carcinoma outside up-to-seven criteria: Strategies using degradable starch microspheres transcatheter arterial chemo-embolization. <i>World Journal of Hepatology</i> , 2015, 7, 1694.	0.8	24
58	A simple rule to personalize standard dual therapy across all genotypes in naive chronic hepatitis C patients: The TT4 randomized trial. <i>Digestive and Liver Disease</i> , 2014, 46, 164-169.	0.4	3
59	Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin. <i>Journal of Hepatology</i> , 2014, 60, 16-21.	1.8	25
60	Comparative evaluation of percutaneous laser and radiofrequency ablation in patients with HCC smaller than 4 cm. <i>Radiologia Medica</i> , 2014, 119, 298-308.	4.7	28
61	An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2014, 46, 818-825.	0.4	8
62	Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: Potent antiviral activity but no clinical benefit if treatment is given late. <i>Digestive and Liver Disease</i> , 2014, 46, 923-927.	0.4	95
63	Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C. <i>Digestive and Liver Disease</i> , 2014, 46, 440-445.	0.4	3
64	A Bayesian methodology to improve prediction of early graft loss after liver transplantation derived from the Liver Match study. <i>Digestive and Liver Disease</i> , 2014, 46, 340-347.	0.4	18
65	White Paper of Italian Gastroenterology: Delivery of services for digestive diseases in Italy: Weaknesses and strengths. <i>Digestive and Liver Disease</i> , 2014, 46, 579-589.	0.4	40
66	Donor-Recipient Matching in HCV-Infected Patients. , 2014, , 15-27.		0
67	A Randomized Controlled Trial of Sequential Pegylated Interferon- $\alpha$ and Telbivudine or <i>Vice Versa</i> for 48 Weeks in Hepatitis B E Antigen-Negative Chronic Hepatitis B. <i>Antiviral Therapy</i> , 2013, 18, 57-64.	0.6	18
68	Skills and Requirements of a Transplant Hepatologist: Board Certification of the Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , 2013, 45, 992-994.	0.4	3
69	The Tor Vergata weaning of immunosuppression protocols in stable hepatitis C virus liver transplant patients: the 10-year follow-up. <i>Transplant International</i> , 2013, 26, 259-266.	0.8	30
70	Hepatitis B-core antibody positive donors in liver transplantation and their impact on graft survival: Evidence from the Liver Match cohort study. <i>Journal of Hepatology</i> , 2013, 58, 715-723.	1.8	44
71	A survey on mortality from non-variceal upper gastrointestinal bleeding: Is the emergency referral system adequate?. <i>Digestive and Liver Disease</i> , 2013, 45, 953-956.	0.4	6
72	Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen. <i>Journal of Infection</i> , 2013, 67, 303-312.	1.7	23

#	ARTICLE	IF	CITATIONS
73	Hepatitis C virus recurrence and immunosuppression-free state after liver transplantation. <i>Expert Review of Clinical Immunology</i> , 2012, 8, 635-644.	1.3	8
74	Leptin attenuates ischemia-reperfusion injury in the rat liver. <i>Transplant International</i> , 2012, 25, 1282-1288.	0.8	8
75	Liver Elasticity in NASH Patients Evaluated with Real-Time Elastography (RTE). <i>Ultrasound in Medicine and Biology</i> , 2012, 38, 537-544.	0.7	42
76	Vitamin D3 modulates T lymphocyte responses in hepatitis C virus-infected liver transplant recipients. <i>Digestive and Liver Disease</i> , 2012, 44, 67-73.	0.4	6
77	Unexplained hepatic deterioration—Keep in mind hepatitis E virus infection!. <i>Digestive and Liver Disease</i> , 2012, 44, 895-896.	0.4	0
78	Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. <i>Antiviral Research</i> , 2012, 93, 86-93.	1.9	71
79	HCV Genotypes Are Differently Prone to the Development of Resistance to Linear and Macrocytic Protease Inhibitors. <i>PLoS ONE</i> , 2012, 7, e39652.	1.1	78
80	Liver Match, a prospective observational cohort study on liver transplantation in Italy: Study design and current practice of donor–recipient matching. <i>Digestive and Liver Disease</i> , 2011, 43, 155-164.	0.4	69
81	Liver transplantation for the treatment of nodular regenerative hyperplasia. <i>Digestive and Liver Disease</i> , 2011, 43, 929-934.	0.4	19
82	Author's reply: Comment to “Liver Match, a prospective observational cohort study on liver transplantation in Italy”. <i>Digestive and Liver Disease</i> , 2011, 43, 921-922.	0.4	0
83	Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence. <i>Journal of Hepatology</i> , 2011, 55, 587-593.	1.8	78
84	Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development. <i>Digestive and Liver Disease</i> , 2011, 43, 975-983.	0.4	28
85	Long-term, maintenance MMF monotherapy improves the fibrosis progression in liver transplant recipients with recurrent hepatitis C. <i>Transplant International</i> , 2011, 24, 461-468.	0.8	25
86	Liver Contrast Enhanced Ultrasound Perfusion Imaging in the Evaluation of Chronic Hepatitis C Fibrosis: Preliminary Results. <i>Ultrasound in Medicine and Biology</i> , 2011, 37, 1-6.	0.7	33
87	Plasma/erythrocyte ribavirin x100 ratio as an indicator of sustained virological response in HCV genotype 1 patients with early virological response. <i>Antiviral Therapy</i> , 2010, 15, 633-639.	0.6	13
88	One-year vaccination against hepatitis B virus with a MPL-vaccine in liver transplant patients for HBV-related cirrhosis. <i>Transplant International</i> , 2010, 23, 1105-1112.	0.8	35
89	Patterns of chronic hepatitis B in Central Italy: a cross-sectional study. <i>European Journal of Public Health</i> , 2010, 20, 711-713.	0.1	13
90	Maintenance ribavirin monotherapy delays fibrosis progression in liver transplant recipients with recurrent hepatitis C at high risk of progression. <i>Digestive and Liver Disease</i> , 2010, 42, 297-303.	0.4	10

#	ARTICLE	IF	CITATIONS
91	Total and covalently closed circular DNA detection in liver tissue of long-term survivors transplanted for HBV-related cirrhosis. <i>Digestive and Liver Disease</i> , 2010, 42, 578-584.	0.4	35
92	Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia. <i>Digestive and Liver Disease</i> , 2010, 42, 902-907.	0.4	11
93	Update from the Editor in Chief: Expanding our Journal's horizons. <i>Digestive and Liver Disease</i> , 2010, 42, 461.	0.4	0
94	Percutaneous laser ablation of hepatocellular carcinoma in patients with liver cirrhosis awaiting liver transplantation. <i>European Journal of Radiology</i> , 2010, 74, e6-e11.	1.2	21
95	Obscure gastrointestinal bleeding as first symptom of eosinophilic jejunitis in a liver transplant recipient: diagnosis and treatment with single balloon enteroscopy. <i>BMJ Case Reports</i> , 2010, 2010, bcr0520091918-bcr0520091918.	0.2	2
96	A randomized controlled trial of pegylated interferon- $\alpha$ 2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. <i>Antiviral Therapy</i> , 2009, 14, 1165-1174.	0.6	83
97	Comment on the PROVE1 and PROVE2 clinical trials: "œl was taking a picture of rapid virological response with telaprevir, but the background is unfocused!" <i>Hepatology</i> , 2009, 50, 1676-1677.	3.6	2
98	Severe drug induced acute hepatitis associated with use of St John's wort ( <i>Hypericum perforatum</i> ) during treatment with pegylated interferon $\alpha$ . <i>BMJ Case Reports</i> , 2009, 2009, bcr0820080761-bcr0820080761.	0.2	6
99	Percutaneous Cryoablation of Small Hepatocellular Carcinoma with US Guidance and CT Monitoring: Initial Experience. <i>CardioVascular and Interventional Radiology</i> , 2008, 31, 587-594.	0.9	78
100	Primary yolk sac tumor of the liver: incidental finding in a patient transplanted for hepatocellular carcinoma. <i>Transplant International</i> , 2008, 21, 598-601.	0.8	12
101	TUDCA prevents cholestasis and canalicular damage induced by ischemia-reperfusion injury in the rat, modulating PKC $\zeta$ pathway. <i>Transplant International</i> , 2008, 21, 792-800.	0.8	23
102	Recurrent myocardial ischaemia during combination antiviral therapy in a patient with chronic hepatitis C and normal aminotransferase levels. <i>Digestive and Liver Disease</i> , 2008, 40, 785-790.	0.4	6
103	Massive hepatic angiomyolipoma in a young woman with tuberous sclerosis complex: Significant clinical improvement during tamoxifen treatment. <i>Journal of Hepatology</i> , 2008, 48, 1026-1029.	1.8	18
104	The Tor Vergata weaning off immunosuppression protocol in stable HCV liver transplant patients: The updated follow up at 78 months. <i>Transplant Immunology</i> , 2008, 20, 43-47.	0.6	73
105	Morphological and Functional Features of Hepatic Cyst Epithelium in Autosomal Dominant Polycystic Kidney Disease. <i>American Journal of Pathology</i> , 2008, 172, 321-332.	1.9	79
106	Evaluation of the Severity of Chronic Hepatitis C with 3-T1H-MR Spectroscopy. <i>American Journal of Roentgenology</i> , 2008, 190, 1331-1339.	1.0	24
107	Peginterferon $\alpha$ -2a and ribavirin versus peginterferon $\alpha$ -2a monotherapy in early virological responders and peginterferon $\alpha$ -2a and ribavirin versus peginterferon $\alpha$ -2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in na $\alpha$ ve patients with chronic hepatitis C. <i>European Journal of Gastroenterology and Hepatology</i> , 2008, 20, 680-687.	0.8	11
108	Activation of the IGF1 System Characterizes Cholangiocyte Survival During Progression of Primary Biliary Cirrhosis. <i>Journal of Histochemistry and Cytochemistry</i> , 2007, 55, 327-334.	1.3	35



#	ARTICLE	IF	CITATIONS
109	Operational tolerance in clinical liver transplantation: Emerging developments. <i>Transplant Immunology</i> , 2007, 17, 108-113.	0.6	37
110	Switch to 1.5 grams MMF monotherapy for CNJ-related toxicity in liver transplantation is safe and improves renal function, dyslipidemia, and hypertension. <i>Liver Transplantation</i> , 2007, 13, 46-54.	1.3	67
111	Interferon-alpha treatment of hepatitis D induces tuberculosis exacerbation in an immigrant. <i>Journal of Infection</i> , 2007, 54, e223-e226.	1.7	35
112	A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. <i>Journal of Hepatology</i> , 2007, 46, 1009-1017.	1.8	96
113	Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. <i>Journal of Hepatology</i> , 2006, 44, 702-709.	1.8	157
114	Cyclosporine A versus tacrolimus monotherapy. Comparison on bile lipids in the first 3 months after liver transplant in humans. <i>Transplant International</i> , 2006, 19, 389-395.	0.8	10
115	Assembly of biliary lipids in native hepatic bile after orthotopic liver transplantation: A biochemical and ultra-structural study in humans. <i>Hepatology Research</i> , 2006, 35, 215-21.	1.8	2
116	A randomized controlled trial of amantadine plus interferon- $\alpha$ 2a vs. interferon- $\alpha$ 2a alone in naive patients with chronic hepatitis C randomized according to the early virological response to interferon- $\alpha$ 2a monotherapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 19, 339-347.	1.9	11
117	LOW-DOSE HEPATITIS B IMMUNOGLOBULIN GIVEN "ON DEMAND" IN COMBINATION WITH LAMIVUDINE: A HIGHLY COST-EFFECTIVE APPROACH TO PREVENT RECURRENT HEPATITIS B VIRUS INFECTION IN THE LONG-TERM FOLLOW-UP AFTER LIVER TRANSPLANTATION. <i>Transplantation</i> , 2004, 77, 1203-1208.	0.5	52
118	Taurohyodeoxycholate- and tauroursodeoxycholate-induced hypercholeresis is augmented in bile duct ligated rats. <i>Journal of Hepatology</i> , 2003, 38, 136-147.	1.8	14
119	Recurrence of insulin resistant metabolic syndrome following liver transplantation. <i>European Journal of Gastroenterology and Hepatology</i> , 2003, 15, 99-102.	0.8	14
120	Ursodeoxycholate and tauroursodeoxycholate inhibit cholangiocyte growth and secretion of BDL rats through activation of PKC alpha. <i>Hepatology</i> , 2002, 35, 1041-1052.	3.6	122
121	Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. <i>Hepatology</i> , 2002, 35, 176-181.	3.6	174
122	Reply.. <i>Hepatology</i> , 2002, 36, 258-259.	3.6	0
123	Lack of evidence for the Th2 predominance in patients with chronic hepatitis C. <i>Clinical and Experimental Immunology</i> , 2001, 123, 451-458.	1.1	14
124	Tauroursodeoxycholate reduces ischemic damage in human allografts: a biochemical and ultrastructural study. <i>Transplantation Proceedings</i> , 2000, 32, 49-50.	0.3	9
125	Effect of bile salts on oviposition in vitro by <i>Schistosoma mansoni</i> . <i>Parasitology Research</i> , 1999, 85, 421-423.	0.6	10
126	A PILOT STUDY ON THE SAFETY AND EFFECTIVENESS OF IMMUNOSUPPRESSION WITHOUT PREDNISONE AFTER LIVER TRANSPLANTATION. <i>Transplantation</i> , 1999, 67, 1308-1313.	0.5	93



#	ARTICLE	IF	CITATIONS
127	Metabolic Findings After Liver Transplantation Within a Randomised Trial With or Without Steroids. <i>Transplantation Proceedings</i> , 1998, 30, 1447-1448.	0.3	14
128	Chronic liver disease in the Alexandria governorate, Egypt: contribution of schistosomiasis and hepatitis virus infections. <i>Journal of Hepatology</i> , 1997, 26, 236-243.	1.8	121
129	Bile acid kinetics and biliary lipid composition in cystic fibrosis. <i>Journal of Hepatology</i> , 1997, 26, 1156.	1.8	0
130	Bile acids with differing hydrophilic-hydrophobic properties do not influence cytokine production by human monocytes and murine Kupffer cells. <i>Hepatology</i> , 1997, 25, 927-933.	3.6	27
131	Effect of taurohyodeoxycholic acid on biliary lipid secretion in humans. <i>Hepatology</i> , 1997, 25, 1306-1314.	3.6	21
132	N-ethyl-tauroursodeoxycholic acid, a novel deconjugation-resistant bile salt analogue: Effects of acute feeding in the rat. <i>Hepatology</i> , 1995, 22, 887-895.	3.6	2
133	Effect of tauroursodeoxycholic acid on serum liver enzyme and serum lipid levels in patients with chronic active hepatitis. <i>Current Therapeutic Research</i> , 1995, 56, 626-634.	0.5	3
134	Lamellar bodies coexist with vesicles and micelles in human gallbladder bile. Ursodeoxycholic acid prevents cholesterol crystal nucleation by increasing biliary lamellae. <i>Journal of Hepatology</i> , 1995, 22, 642-657.	1.8	14
135	Effect of taurohyodeoxycholic acid, a hydrophilic bile salt, on bile salt and biliary lipid secretion in the rat. <i>Digestive Diseases and Sciences</i> , 1994, 39, 2389-2397.	1.1	23
136	Development and validation of a quantitative assay for cholesterol crystal growth in human gallbladder bile. <i>Lipids and Lipid Metabolism</i> , 1994, 1214, 63-72.	2.6	7
137	Taurine-induced diuresis and natriuresis in cirrhotic patients with ascites. <i>Life Sciences</i> , 1994, 54, 1585-1593.	2.0	17
138	Nodular transformation of the liver: A reply. <i>Gastroenterology</i> , 1993, 105, 1593-1594.	0.6	1
139	Molecular composition of biliary phosphatidylcholines, as related to cholesterol saturation, transport and nucleation in human gallbladder bile. <i>Journal of Hepatology</i> , 1992, 15, 59-66.	1.8	30
140	Differential patterns of lipid-protein association in fast and slow cholesterol nucleating human gallbladder biles: implications for cholesterol nucleation from biliary lipid carriers. <i>Lipids and Lipid Metabolism</i> , 1991, 1086, 125-133.	2.6	6
141	Impaired hepatic handling and processing of lysophosphatidylcholine in rats with liver cirrhosis. <i>Gastroenterology</i> , 1991, 101, 228-237.	0.6	10
142	Fulminant hepatic failure. <i>Digestive Diseases and Sciences</i> , 1991, 36, 775-779.	1.1	43
143	Improvement of estradiol 17 $\beta$ -D-glucuronide cholestasis by intravenous administration of dimethylethanolamine in the rat. <i>Hepatology</i> , 1991, 13, 1158-1172.	3.6	17
144	Gallstones in cystic fibrosis: A critical reappraisal. <i>Hepatology</i> , 1991, 14, 768-775.	3.6	73

#	ARTICLE	IF	CITATIONS
145	Biliary Sludge. <i>Journal of Clinical Gastroenterology</i> , 1990, 12, 656-662.	1.1	24
146	Spontaneous formation of pigmentary precipitates in bile salt-depleted rat bile and its prevention by micelle-forming bile salts. <i>Gastroenterology</i> , 1990, 98, 444-453.	0.6	18
147	Prevalence of gallstones in patients with primary immunoglobulin deficiency. <i>Digestive Diseases and Sciences</i> , 1990, 35, 716-720.	1.1	4
148	Physico-chemical factors predisposing to pigment gallstone formation in liver cirrhosis. <i>Journal of Hepatology</i> , 1990, 10, 228-234.	1.8	40
149	Selective hepatic enrichment of polyunsaturated phosphatidylcholines after intravenous administration of dimethylethanolamine in the rat. <i>Lipids and Lipid Metabolism</i> , 1989, 1006, 116-120.	2.6	4
150	Transport, utilization and biliary secretion of lysophosphatidylcholine in the rat liver. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1987, 905, 91-99.	1.4	9
151	Clinical and hormonal conditions associated with sodium retention in cirrhotic patients with ascites. <i>Digestive Diseases and Sciences</i> , 1987, 32, 569-576.	1.1	6
152	Sulfated bile acids in serum, bile, and urine of cirrhotic patients before and after portacaval anastomosis. <i>Digestive Diseases and Sciences</i> , 1981, 26, 513-517.	1.1	15
153	Effect of Glucose and/or Branched Chain Amino Acid Infusion on Plasma Amino Acid Imbalance in Chronic Liver Failure. <i>Journal of Parenteral and Enteral Nutrition</i> , 1981, 5, 414-419.	1.3	36
154	Individual serum bile acids in patients with primary hyperlipoproteinemias. <i>Atherosclerosis</i> , 1980, 37, 293-299.	0.4	1
155	Influence of portacaval anastomosis on serum and biliary unsulfated bile acid composition in patients with liver cirrhosis. <i>Digestive Diseases and Sciences</i> , 1979, 24, 829-834.	1.1	4